Extract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has disrupted clinical trials worldwide [1]. This could delay the approval of new medicines and reduce access to investigational treatments via clinical trials. This particularly impacts patients with rare diseases such as cystic fibrosis (CF).
Abstract
Rare disease patients may suffer delayed access to new drugs as SARS-CoV-2 is disrupting clinical trials. This survey demonstrates that the European Cystic Fibrosis Clinical Trials Network is ideally placed to track and address such disruption. https://bit.ly/3hCw5dq
Footnotes
Conflict of interest: S. van Koningsbruggen-Rietschel reports grants from Algipharma (HORIZON2020), personal fees from Deutsches Zentrum für Infektionsforschung, Antabio, Proteostasis Therapeutics, Roche and Vertex Pharmaceuticals, outside the submitted work.
Conflict of interest: F. Dunlevy has nothing to disclose.
Conflict of interest: V. Bulteel has nothing to disclose.
Conflict of interest: D.G. Downey reports grants and personal fees from Vertex, Proteostasis and Chiesi, outside the submitted work.
Conflict of interest: L. Dupont has nothing to disclose.
- Received June 2, 2020.
- Accepted July 20, 2020.
- Copyright ©ERS 2020
This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.